Skip to content

Released Aug 14, 2017, after the close

10-Q filed Aug 14, 2017, 45 days after period end · 0001564590-17-017677

Q2 2017 · 10-Q
Revenue$1.03M−0.1% vs Q2 2016−0.1% vs Q1 2017
Net Income-$9.65MN/M vs Q2 2016N/M vs Q1 2017
EPS Diluted-$0.23N/M vs Q2 2016N/M vs Q1 2017
Operating Income-$9,570,000N/M
Operating Cash Flowderived-$8,872,000N/M
Free Cash Flowderived-$9,283,000N/M
Margins · derived
Operating margin-932.7%−153.4 pt vs Q2 2016
Net margin-940.1%−121.4 pt vs Q2 2016

What the release said

The release

Same quarter

MetricQ2 2017Q2 2016Q2 2015Q2 2014
Revenue$1.03M$1.03M$329.00K—
Net Income-$9.65M-$8.41M-$7.78M-$6.07M
EPS Diluted-$0.23-$0.29-$0.33-$0.30

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR